This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-36. (Canceled)

37. (currently amended) A method of identifying a modulator of CCX CKR activity, comprising:

(a) contacting a cell expressing a CCX CKR polypeptide ~~having an amino acid sequence as set forth in SEQ ID NO:2, or variant or fragment thereof, that binds at least one of the chemokines ELC, SLC and TECK and~~ with a test compound in the presence of a chemokine selected from the group consisting of ELC (EBI-1-ligand chemokine), SLC (secondary lymphoid organ chemokine), TECK (thymus expressed chemokine), BLC (B-lymphocyte chemoattractant), CTACK (cutaneous T cell attracting chemokine), mMIP-1γ (murine macrophage inflammatory protein-1γ), or vMIPII (viral macrophage inflammatory protein II), wherein

the CCX CKR polypeptide comprises an amino acid sequence selected from the group consisting of : (i) an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:2, and (ii) a fragment of the amino acid sequence of (i); and

the CCX CKR polypeptide separately can specifically bind at least two of the chemokines listed in (a) in the absence of the test compound; and

(b) detecting modulation of a biological activity in the presence of the test compound, wherein modulation of the biological activity indicates that the test compound is a modulator of CCX CKR activity.

38. (previously presented) The method of claim 37, wherein the biological activity is selected from the group consisting of receptor internalization, intracellular signaling activity, and intracellular second messenger levels.

39. (previously presented) The method of claim 37, wherein the biological activity is selected from the group consisting of chemotaxis, cell proliferation, and an inflammatory response.

40. (currently amended) The method of claim 37, wherein the ~~cell expresses a recombinant~~ CCX CKR polypeptide~~, fragment or variant~~ is a recombinant CCX CKR polypeptide.

41. (currently amended) The method of claim 37, wherein contacting occurs in the presence of ~~the chemokine is~~ ELC.

42. (currently amended) The method of claim 37, wherein contacting occurs in the presence of ~~the chemokine is~~ SLC.

43. (currently amended) The method of claim 37, wherein contacting occurs in the presence of ~~the chemokine is~~ TECK.

44. (currently amended) The method of claim 37, wherein contacting occurs in the presence of ~~the chemokine is~~ BLC.

45. (currently amended) The method of claim 37, wherein contacting occurs in the presence of ~~the chemokine is~~ CTACK.

46. (currently amended) The method of claim 37, wherein contacting occurs in the presence of ~~the chemokine is~~ mMIP-1γ.

47. (currently amended) The method of claim 37, wherein contacting occurs in the presence of ~~the chemokine is~~ vMIPII.

48. (withdrawn) A process for providing a pharmaceutical composition, comprising conducting the steps of a method of claim 37 and thereafter formulating a modulator of CCX CKR activity for pharmaceutical use.

49. (new) The method of claim 37, wherein the amino acid sequence of the CCX CKR polypeptide has at least 95% sequence identity to SEQ ID NO:2.

50. (new) The method of claim 49, wherein the amino acid sequence of the CCX CKR polypeptide has at least 98% sequence identity to SEQ ID NO:2.

51. (new) The method of claim 37, wherein the CCX CKR polypeptide is a fragment of SEQ ID NO:2.

52. (new) The method of claim 37, wherein one of the at least two chemokines is TECK.

53. (new) The method of claim 37, wherein the CCX CKR polypeptide separately can specifically bind at least three of the chemokines listed in (a) in the absence of the test compound.

54. (new) The method of claim 37, wherein the CCX CKR polypeptide can individually bind all of the chemokines listed in (a) in the absence of the test compound.

55. (new) A method of identifying a modulator of CCX CKR activity, comprising:

(a) contacting a cell expressing a CCX CKR polypeptide with a test compound in the presence of a chemokine selected from the group consisting of ELC (EBI-1-ligand chemokine), SLC (secondary lymphoid organ chemokine), TECK (thymus expressed chemokine), BLC (B-lymphocyte chemoattractant), CTACK (cutaneous T cell attracting chemokine), mMIP-1γ (murine macrophage inflammatory protein-1γ), or vMIPII (viral macrophage inflammatory protein II), wherein

the CCX CKR polypeptide comprises an amino acid sequence selected from the group consisting of : (i) an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:2, and (ii) a fragment that comprises at least 100 contiguous amino acids of the sequence of (i); and

the CCX CKR polypeptide can bind at least one of the chemokines listed in (a) in the absence of test compound; and

(b) detecting modulation of a biological activity in the presence of the test compound, wherein modulation of the biological activity indicates that the test compound is a modulator of CCX CKR activity.

56. (new) The method of claim 55, wherein the biological activity is selected from the group consisting of receptor internalization, intracellular signaling activity, and intracellular second messenger levels.

57. (new) The method of claim 55, wherein the biological activity is selected from the group consisting of chemotaxis, cell proliferation, and an inflammatory response.

58. (new) The method of claim 55, wherein the CCX CKR polypeptide is a recombinant CCX CKR polypeptide.

59. (new) The method of claim 55, wherein contacting occurs in the presence of ELC.

60. (new) The method of claim 55, wherein contacting occurs in the presence of SLC.

61. (new) The method of claim 55, wherein contacting occurs in the presence of TECK.

62. (new) The method of claim 55, wherein contacting occurs in the presence of BLC.

63. (new) The method of claim 55, wherein contacting occurs in the presence of CTACK.

64. (new) The method of claim 55, wherein contacting occurs in the presence of mMIP-1γ.

65. (new) The method of claim 55, wherein contacting occurs in the presence of vMIPII.

66. (new) The method of claim 55, wherein the amino acid sequence of the CCX CKR polypeptide has at least 95% sequence identity to SEQ ID NO:2.

67. (new) The method of claim 66, wherein the amino acid sequence of the CCX CKR polypeptide has at least 98% sequence identity to SEQ ID NO:2.

68. (new) The method of claim 55, wherein the CCX CKR polypeptide is a fragment of SEQ ID NO:2.

69. (new) The method of claim 55, wherein the CCX CKR polypeptide can individually bind a plurality of the chemokines listed in (a) in the absence of the test compound.

70. (new) The method of claim 69, wherein the CCX CKR polypeptide can individually bind all of the chemokines listed in (a) in the absence of the test compound.